Last quote by Nina Devlin
Mylan received an information request from the FTC months ago as part of a preliminary investigation. Any suggestion that Mylan took any inappropriate or unlawful actions to prevent generic competition is without merit. We note that the epinephrine auto-injector market is and always has been competitive, with multiple products competing on the market since we acquired EpiPen Auto-Injector. Further, Teva has had patent licenses to launch their proposed generic alternative to EpiPen Auto-Injector since June 2015, pending FDA approval, years prior to patent expiry.
Jan 30 2017
We can learn a lot about a person if we know what types of things he or she talks about or comments on the most frequently. There are numerous topics with which Nina Devlin is associated, including Mylan and Tricare. Most recently, Nina Devlin has been quoted saying: “It was always our intention that the reclassification would benefit all government agencies impacted by the classification, including the VA and Tricare (Defense) programs.” in the article EpiPen price hikes add millions to Pentagon costs. An other article where Nina Devlin has been quoted is New York attorney general investigates EpiPen manufacturer.
Quotes by Nina Devlin
Oct 28 2016
It was always our intention that the reclassification would benefit all government agencies impacted by the classification, including the VA and Tricare (Defense) programs.
Sep 06 2016
The program continues to adhere to all applicable laws and regulations.
Sep 06 2016
There are no purchase requirements for participation in the program, nor have there ever been to receive free EpiPen auto-injectors.
Sep 01 2016
The board has been actively engaged in overseeing the execution of Mylan's growth strategy over the past decade - a strategy which has brought hundreds of products to the market.
Aug 24 2016
We have reached out to every member of Congress who has sent us a letter, and we look forward to meeting with them and responding to their questions as soon as possible.
Jun 10 2016
Mylan's business model is not today, nor has it ever been, premised on price hikes.
Jun 10 2016
Mylan has always been known to have one of the industry's broadest and most globally diversified business models and portfolios, which we have successfully managed by balancing numerous variables, including the natural price reductions that have always been inherent to the generics industry.
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided